CK Life Sciences to post $126.6m loss in 2024
It was due to increased research and development investments.
CK Life Sciences International expects to report a loss attributable to shareholders of $126.6m for financial year 2024, compared to a profit of $17.3m for 2023.
The company said this was due to increased research and development investments and a decline in the fair value of the vineyard portfolio.
Overall, the group said operations remained stable throughout the year. Further details will be disclosed on 18 March 2025.